Atsushi Ono

28PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersHaematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 22, 2026
Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

|May 04, 2026
A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

|Mar 25, 2026
Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Atsushi Ono, Ryoichi Miura, C Nelson Hayes

|Feb 07, 2026
Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda

|Dec 12, 2025
Do Asian patients with HCC derive greater benefit from anti-PD-L1 plus anti-CTLA-4 therapy?

Atsushi Ono, C Nelson Hayes, Masataka Tsuge

|Oct 29, 2025
Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients.

Keiichi Hiraoka, Masataka Tsuge, Michihiko Kawahara

Pageof 5

Frequent Collaborators

13 joint publications

Shinsuke Uchikawa

11 joint publications

Masataka Tsuge

10 joint publications

Hatsue Fujino

7 joint publications

Eisuke Murakami